Q-omics provides the consensus-scored MIR548XHG profile across patient tissues and cancer cell-line models. MIR548XHG expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR548XHG is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, MIR548XHG RNA expression shows 8,102 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUSC, and TGCT as cancer lineages where MIR548XHG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548XHG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548XHG survival associations across molecular data types. MIR548XHG RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548XHG RNA expression–survival associations across cancer types. High MIR548XHG expression shows unfavorable associations in KIRC, KICH, UVM, LUAD and DLBC, but favorable associations in GBM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR548XHG RNA expression.
This table summarizes MIR548XHG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548XHG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548XHG shows higher tumor expression in LUSC, LIHC, BRCA, UCEC, LUAD and HNSC. The LUSC box plot shows higher MIR548XHG RNA expression in tumor versus normal tissue (log2 FC = +0.795, t-test p < 0.001).
This table shows molecular features associated with MIR548XHG in patient tissues and cancer cell lines. In patient samples, MIR548XHG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
